Recombinant Human CD274 protein

中文名： 白细胞分化抗原274(CD274)重组蛋白
别名： CD274；B7H1；PDCD1L1；PDCD1LG1；Programmed cell death 1 ligand 1

货号: PA1000-497DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95 % SDS-PAGE.
种属	Human
靶点	CD274
Uniprot No	Q9NZQ7
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	19-238aa
氨基酸序列	FTVTVPKDLY VVEYGSNMTI ECKFPVEKQL DLAALIVYWE MEDKNIIQFV HGEEDLKVQH SSYRQRARLL KDQLSLGNAA LQITDVKLQD AGVYRCMISY GGADYKRITV KVNAPYNKIN QRILVVDPVT SEHELTCQAE GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFNVTSTLR INTTTNEIFY CTFRRLDPEE NHTAELVIPE LPLAHPPNER
预测分子量	25 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CD274(PD-L1)重组蛋白的3篇参考文献及其摘要概括：

---

1. **文献名称**: *Expression and purification of recombinant human PD-L1 protein in Escherichia coli for cancer research*

**作者**: Li, H., et al.

**摘要**: 该研究报道了在大肠杆菌中高效表达和纯化人源CD274重组蛋白的方法，通过优化密码子和纯化步骤获得高纯度蛋白，验证其与PD-1的结合活性，为免疫检查点抑制剂的体外筛选提供工具。

---

2. **文献名称**: *Structural characterization of glycosylated CD274 recombinant protein expressed in mammalian cells*

**作者**: Zhang, Y., et al.

**摘要**: 利用哺乳动物细胞表达系统制备糖基化CD274重组蛋白，通过质谱和生物层干涉技术分析其糖基化修饰及与PD-1的亲和力，揭示翻译后修饰对其免疫调节功能的影响。

---

3. **文献名称**: *Functional analysis of PD-L1 recombinant protein in modulating T-cell responses*

**作者**: Wang, Q., et al.

**摘要**: 研究通过体外实验验证重组CD274蛋白对T细胞活化的抑制作用，证明其通过PD-1/PD-L1通路降低T细胞增殖和细胞因子分泌，为肿瘤免疫治疗机制研究提供实验依据。

---

(注：以上为示例文献，实际引用需根据具体研究补充真实文献信息。)

背景信息

CD274. commonly known as programmed death-ligand 1 (PD-L1), is a transmembrane protein that plays a critical role in immune regulation by suppressing T-cell activation. It interacts with the PD-1 receptor on immune cells, delivering inhibitory signals to dampen immune responses, a mechanism exploited by tumors to evade immune surveillance. Overexpression of PD-L1 in cancer cells correlates with poor prognosis, making it a key target for immunotherapy.

Recombinant CD274 protein is engineered in vitro using expression systems such as *E. coli*, mammalian cells, or insect cells to produce soluble or membrane-bound forms. This protein retains the functional PD-1-binding domain, enabling researchers to study PD-1/PD-L1 interactions in structural, biochemical, and cellular assays. Mammalian-derived CD274 often includes post-translational modifications (e.g., glycosylation), which may influence its stability and binding properties, while bacterial systems yield non-glycosylated versions suitable for cost-effective bulk production.

In therapeutic development, recombinant CD274 is used to screen and validate inhibitors (e.g., monoclonal antibodies like pembrolizumab) that block PD-1/PD-L1 signaling, revitalizing antitumor immunity. It also serves as a critical reagent in diagnostic assays to quantify PD-L1 expression in patient samples, aiding in predicting immunotherapy responses. Additionally, structural studies using recombinant protein have elucidated binding epitopes, guiding the design of next-generation immunotherapies.

Challenges in its application include maintaining native conformation and activity during production, particularly for glycosylated forms. Despite this, recombinant CD274 remains indispensable in advancing cancer immunotherapy research and biomarker discovery, underscoring its dual role as a therapeutic target and a tool for mechanistic exploration. Ongoing efforts focus on optimizing expression platforms and improving functional mimicry of the native protein.